Mereo BioPharma (MREO) Net Cash Flow (2023 - 2026)

Mereo BioPharma (MREO) has reported Net Cash Flow for 4 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 43.94% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.0 million (down 306.83% YoY) and the FY2025 annual result came in at -$30.7 million, down 343.09% from the prior year.
• Net Cash Flow climbed to -$4.6 million in Q1 2026 per MREO's latest filing, from -$7.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for MREO reached as high as $38.9 million in Q2 2024 and fell as low as -$9.7 million in Q1 2023.
• A 4-year average of -$2.4 million and a median of -$7.7 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 176.79% — and 2026, when it jumped 43.94%.
• Year by year, Net Cash Flow stood at -$6.8 million in 2023, then plunged by 39.34% to -$9.5 million in 2024, then climbed by 19.21% to -$7.6 million in 2025, then soared by 39.66% to -$4.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$4.6 million, -$7.6 million, and -$7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.